89180-90-5

Basic information

• Product Name: 5-(CHLOROMETHYL)-1-METHYL-1H-IMIDAZOLE
• Synonyms: 5-(CHLOROMETHYL)-1-METHYL-1H-IMIDAZOLE;5-(chloromethyl)-1-methyl-1H-imidazole(SALTDATA: HCl 0.23H2O);5-(ChloroMethyl)-1-MethyliMidazole
• CAS NO: 89180-90-5
• Molecular Formula: C₅H₇ClN₂
• Molecular Weight: 130.58
• EINECS: 604-604-1
• Mol File: 89180-90-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 284.667°C at 760 mmHg
• Flash Point: 125.963°C
• Appearance: /
• Density: 1.208g/cm³
• Vapor Pressure: 0.005mmHg at 25°C
• Refractive Index: 1.551
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-(CHLOROMETHYL)-1-METHYL-1H-IMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(CHLOROMETHYL)-1-METHYL-1H-IMIDAZOLE(89180-90-5)
• EPA Substance Registry System: 5-(CHLOROMETHYL)-1-METHYL-1H-IMIDAZOLE(89180-90-5)

Safety Data

• Hazardous Substances Data: 89180-90-5(Hazardous Substances Data)

Usage

General Description

5-(Chloromethyl)-1-methyl-1H-imidazole is a chemical compound with the molecular formula C5H7ClN2. It is a derivative of imidazole, a heterocyclic compound that contains a five-membered ring with three carbon atoms and two nitrogen atoms. 5-(CHLOROMETHYL)-1-METHYL-1H-IMIDAZOLE is used in organic synthesis as a building block for pharmaceuticals and agrochemicals. It is also used as a reagent in the synthesis of various compounds, including drugs and coordination complexes. The chloromethyl group makes this compound a reactive intermediate, and it can undergo various chemical reactions to form different products. 5-(CHLOROMETHYL)-1-METHYL-1H-IMIDAZOLE is also known for its potential use in the treatment of certain diseases and is currently being studied for its pharmacological properties.

InChI:InChI=1/C5H7ClN2/c1-8-4-7-3-5(8)2-6/h3-4H,2H2,1H3

Upstream product

• 66787-70-0 ethyl 1-methyl-1H-imidazole-5-carboxylate 
• 17289-20-2 methyl 1-methyl-1H-imidazole-5-carboxylate 
• 41064-98-6 3-methyl-3H-imidazole-4-carboxylic acid N'-benzenesulfonyl-hydrazide 
• 23585-00-4 1-methyl-1H-imidazole-5-carboxylic acid hydrazide 
• 39021-62-0 1-methylimidazole-5-carbaldehyde 
• 38993-84-9 (1-methyl-1H-imidazol-5-yl)methanol 

Downstream Products

• 865788-38-1 (2-{N-(4-bromophenyl)-N-[(3-methyl-3H-imidazol-4-yl)methyl]amino}ethyl)carbamic acid tert-butyl ester 
• 865788-39-2 (2-{N-(4-cyanophenyl)-N-[(3-methyl-3H-imidazol-4-yl)methyl]amino}ethyl)carbamic acid tert-butyl ester 
• 865788-41-6 N'-benzyl-N-(4-bromophenyl)-N-[(3-methyl-3H-imidazol-4-yl)methyl]ethane-1,2-diamine 
• 865788-42-7 4-{N-[2-(benzylamino)ethyl]-N-[(3-methyl-3H-imidazol-4-yl)methyl]amino}benzonitrile 
• 865788-46-1 4-{N-[2-(2-methylbenzylamino)ethyl]-N-[(3-methyl-3H-imidazol-4-yl)methyl]amino}benzonitrile 
• 865788-44-9 N-tert-butyl-2-(2-{N-(4-cyanophenyl)-N-[(3-methyl-3H-imidazol-4-yl)methyl]amino}ethylamino)acetamide 
• 865788-43-8 4-(N-{2-[(cyclohexylmethyl)amino]ethyl}-N-[(3-methyl-3H-imidazol-4-yl)methyl]amino)benzonitrile 

Relevant articles and documents

2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG

The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.

Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites

Third world nations require immediate access to inexpensive therapeutics to counter the high mortality inflicted by malaria. Here, we report a new class of antimalarial protein farnesyltransferase (PFT) inhibitors, designed with specific emphasis on simple molecular architecture, to facilitate easy access to therapies based on this recently validated antimalarial target. This novel series of compounds represents the first Plasmodium falciparum selective PFT inhibitors reported (up to 145-fold selectivity), with lead inhibitors displaying excellent in vitro activity (IC50 50 100 nM). Initial studies of absorption, metabolism, and oral bioavailability are reported.

Structurally simple farnesyltransferase inhibitors arrest the growth of malaria parasites

(Chemical Equation Presented) Antimalarial compounds: Structurally simple acyclic inhibitors of protein farnesyltransferase (active-site model shown) from the malaria parasite Plasmodium falciparum may allow third world countries access to an effective and inexpensive antimalarial therapy to counter the estimated half billion infections that occur annually.